The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and regulatory review in Europe is ongoing. We estimate the population potentially eligible for treatment with lecanemab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jönsson, Linus, Wimo, Anders, Handels, Ron, Johansson, Gunilla, Boada, Mercè, Engelborghs, Sebastiaan, Frölich, Lutz, Jessen, Frank, Kehoe, Patrick Gavin, Kramberger, Milica, de Mendonςa, Alexandre, Ousset, Pierre Jean, Scarmeas, Nikolaos, Visser, Pieter Jelle, Waldemar, Gunhild, Winblad, Bengt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220264/
https://www.ncbi.nlm.nih.gov/pubmed/37251789
http://dx.doi.org/10.1016/j.lanepe.2023.100657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220264/
https://www.ncbi.nlm.nih.gov/pubmed/37251789
http://dx.doi.org/10.1016/j.lanepe.2023.100657

Ejemplares similares